Supernus Pharmaceuticals Inc share price logo

Supernus Pharmaceuticals Inc Share Price

NASDAQ: SUPN

Small Cap

$44.80

+0.81

(+1.84%)

as on

Supernus Pharmaceuticals Inc Stock Performance

as on September 18, 2025 at 1:29 am IST

  • Day's Low

    Day's High

    $43.89
    $45.16
    downward going graph

    2.03%

    Downside

    0.80%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $29.16
    $46.79
    downward going graph

    34.91%

    Downside

    4.43%

    Upside

    downward going graph

Supernus Pharmaceuticals Inc share price movements today

Previous Close
$43.99
Open
$44.04
Volume
649.6K
Day's Low - High
$43.89 - $45.16
52 Week Low - High
$29.16 - $46.79

Supernus Pharmaceuticals Inc Historical Returns

1 Month Return
+ 3.05 %
3 Month Return
+ 36.09 %
1 Year Return
+ 38.68 %
3 Year Return
+ 26.05 %
5 Year Return
+ 95.69 %

Supernus Pharmaceuticals Inc Stock Fundamentals & Key Indicators

Check Supernus Pharmaceuticals Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.5B

EPS (TTM)

2.2233

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.11%

PE Ratio (TTM)

38.25

Industry PE ratio

-3.9281873111782475

P/B Ratio

38.2522

PEG Ratio

1.47

EBITDA

132.2M

Revenue (TTM)

665.1M

Profit Margin

9.70%

Return On Equity TTM

6.38%

Supernus Pharmaceuticals Inc Stock Valuation

Track how Supernus Pharmaceuticals Inc P/E has moved over time to understand its valuation trends.

Supernus Pharmaceuticals Inc in the last 5 years

  • Overview

  • Trends

Lowest (9.12x)

December 31, 2020

Industry (-3.93x)

September 17, 2025

Today (38.25x)

September 17, 2025

Highest (50.84x)

September 30, 2022

LowHigh

Today’s Price to Earnings Ratio: 38.25x

Supernus Pharmaceuticals Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Supernus Pharmaceuticals Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$2.5B95.69%38.259.70%
BUY$18.0BNA15.5240.36%
BUY$44.0BNA21.5113.81%
BUY$14.0B38.31%41.6913.88%
BUY$65.4B-8.86%25.3827.83%

Stock Returns calculator for Supernus Pharmaceuticals Inc Stock including INR - Dollar returns

The Supernus Pharmaceuticals Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Supernus Pharmaceuticals Inc investment value today

Current value as on today

₹1,45,834

Returns

₹45,834

(+45.83%)

Returns from Supernus Pharmaceuticals Inc Stock

₹41,236 (+41.24%)

Dollar Returns*

₹4,598 (+4.6%)

Analyst Recommendation on Supernus Pharmaceuticals Inc Stock

Based on 10 analysts

BUY

80.00%

Buy

20.00%

Hold

0.00%

Sell

Based on 10 analysts, 80% of analysts recommend a 'BUY' rating for Supernus Pharmaceuticals Inc. Average target price of $43.8

Supernus Pharmaceuticals Inc Share Price Target

Get share price movements and forecasts by analysts on Supernus Pharmaceuticals Inc.

What analysts predicted

-2.28%DOWNSIDE

Target Price

$43.8

Current Price

$44.8

Analyzed by

10 Analysts

Target

$43.80

Supernus Pharmaceuticals Inc target price $43.8, a slight downside of -2.28% compared to current price of $44.8. According to 10 analysts rating.

Supernus Pharmaceuticals Inc Stock's Interest Amongst Investors

Search interest for Supernus Pharmaceuticals Inc Stock has decreased by -30% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-30% versus previous 30 day period

Supernus Pharmaceuticals Inc Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
153
135
153
164
143
168
175
174
149
165
Gross Profit
130
114
134
123
106
129
138
148
134
127
Operating Income
8
-17
8
18
-4
18
40
21
-10
11
EBITDA
24
4
29
40
16
38
65
45
17
37
Interest Expense
1
0
-
4
-
-
-
-
-
-
Depreciation
19
20
21
21
20
20
20
18
20
21
Income Before Tax
9
-17
9
0
0
26
44
26
-5
16
Income Tax Expense
-7
-16
25
0
0
6
6
11
5
-5
Net Income
16
0
-15
1
0
19
38
15
-11
22
Net Profit Margin
11.02%
-0.61%
-10.38%
0.72%
0.09%
11.83%
21.91%
8.80%
-7.89%
13.60%

Supernus Pharmaceuticals Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2015
Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
144
215
302
408
392
520
579
667
607
661
Gross Profit
136
203
287
393
376
467
504
580
523
583
Operating Income
17
54
99
144
148
173
86
67
-5
81
EBITDA
21
56
107
151
180
212
129
153
90
178
Interest Expense
4
5
1
18
22
23
23
7
2
-
Depreciation
-
-
8
7
6
18
32
82
84
80
Income Before Tax
14
50
100
140
147
168
73
60
2
97
Income Tax Expense
0
-40
43
29
34
41
19
0
1
24
Net Income
14
91
57
110
113
126
53
60
1
73
Net Profit Margin
9.70%
42.43%
18.95%
27.14%
28.79%
24.39%
9.21%
9.10%
0.22%
11.16%

Supernus Pharmaceuticals Inc Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
0
-15
1
0
19
38
15
-11
22
Operating Cash Flow
-18
35
44
38
35
53
44
30
58
Investing Cash Flow
60
34
-65
-51
-48
-77
-12
37
-30
Financing Cash Flow
-478
0
1
1
1
3
5
-21
0
Change in Cash
-437
70
-19
-11
-11
-20
37
46
28

Supernus Pharmaceuticals Inc Annual Cash Flow

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
91
57
110
113
126
53
60
1
73
Operating Cash Flow
66
114
128
143
138
127
116
111
171
Investing Cash Flow
-35
-86
-413
-157
-34
-81
-216
268
-189
Financing Cash Flow
2
5
376
3
3
-130
-10
-397
12
Change in Cash
32
33
91
-10
107
-85
-110
-18
-5

Global Institutional Holdings in Supernus Pharmaceuticals Inc

Funds
Holdings
BlackRock Inc
17.27%
Vanguard Group Inc
10.99%
Armistice Capital, LLC
9.27%
Dimensional Fund Advisors, Inc.
5.18%
Macquarie Group Ltd
4.81%

Insights on Supernus Pharmaceuticals Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, SUPN has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -11.82M → 22.49M (in $), with an average increase of 152.6% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 149.82M → 165.45M (in $), with an average increase of 9.5% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, United Therapeutics Corporation has given 82.5% return, outperforming this stock by 56.5%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, SUPN stock has moved down by -4.8%

About Supernus Pharmaceuticals Inc

pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.
OrganisationSupernus Pharmaceuticals Inc
Headquarters9715 Key West Avenue, Rockville, MD, United States, 20850
IndustryHealth Technology
CEOMr. Jack A. Khattar M.B.A.
E-voting on sharesClick here to vote

Key Management of Supernus Pharmaceuticals Inc

Name

Title

Dr. Padmanabh P. Bhatt Ph.D.

Chief Scientific Officer & Senior VP of Intellectual Property

Mr. Frank Mottola

Senior VP & Chief Technology Operations Officer

Dr. Jonathan Rubin M.B.A., M.D.

Senior VP of Research & Development and Chief Medical Officer

Mr. Kevin T. Anderson Esq.

Compliance Officer

Dr. Todd Horich M.B.A., Ph.D.

Senior Vice President of Marketing, Commercial Operations & Market Access

Mr. Taylor Raiford

Senior Vice President of Sales

Dr. Bryan A. Roecklein Ph.D.

Senior Vice President of Corporate Development

Mr. Jack A. Khattar M.B.A.

Founder, President, CEO, Secretary & Director

Mr. Timothy C. Dec

Senior VP & CFO

Mr. Jeff Bozick

Senior Vice President of Supply Chain

FAQs

What is Supernus Pharmaceuticals Inc share price today?

Supernus Pharmaceuticals Inc share price today is $44.8 as on at the close of the market. Supernus Pharmaceuticals Inc share today touched a day high of $45.16 and a low of $43.89.

What is the 52 week high and 52 week low for Supernus Pharmaceuticals Inc share?

Supernus Pharmaceuticals Inc share touched a 52 week high of $46.79 on and a 52 week low of $29.16 on . Supernus Pharmaceuticals Inc stock price today i.e. is closed at $44.8,which is 4.24% down from its 52 week high and 53.64% up from its 52 week low.

What is Supernus Pharmaceuticals Inc's market capitalisation today?

Supernus Pharmaceuticals Inc market capitalisation is $0.00T as on .

How to invest in Supernus Pharmaceuticals Inc Stock (SUPN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Supernus Pharmaceuticals Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Supernus Pharmaceuticals Inc Shares that will get you 0.0335 shares as per Supernus Pharmaceuticals Inc share price of $44.8 per share as on September 18, 2025 at 1:29 am IST.

What is the minimum amount required to buy Supernus Pharmaceuticals Inc Stock (SUPN) from India?

Indian investors can start investing in Supernus Pharmaceuticals Inc (SUPN) shares with as little as ₹87.816 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹878.16 in Supernus Pharmaceuticals Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Supernus Pharmaceuticals Inc share’s latest price of $44.8 as on September 18, 2025 at 1:29 am IST, you will get 0.2232 shares of Supernus Pharmaceuticals Inc. Learn more about fractional shares .

What are the returns that Supernus Pharmaceuticals Inc has given to Indian investors in the last 5 years?

Supernus Pharmaceuticals Inc stock has given 95.69% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?